Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tumor DNA and immune cells reveal why some cancers resist immunotherapy?

NCT ID NCT07796594

Knowledge-focused Sponsor: Amsterdam UMC, location VUmc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

Researchers at Amsterdam UMC are studying tumor samples from 180 people with advanced melanoma or pancreatic cancer that has stopped responding to immunotherapy. Participants give one extra tumor biopsy and a blood sample. The team will analyze the tumor's full genetic code and the immune cells around it to see how they relate. The goal is to find new targets for future combination treatments and to understand why some tumors are 'inflamed' while others are not.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tumor biopsy and blood draw for whole-genome sequencing and immune profiling
What this could lead to
If successful, this could reveal why some tumors resist immunotherapy and point toward new combination treatments for melanoma and pancreatic cancer.
What could go wrong
This is an early, observational study, so it may not directly lead to new treatments. Biopsies carry small risks like bleeding or infection, and the findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of locally advanced or metastatic cutaneous/mucosal melanoma or pancreatic cancer, meeting the following characteristics: a. Melanoma i. Patients with histologically proven locally advanced or metastatic melanoma (stage IV), with intrinsic or acquired resistance to treatment with immune checkpoint inhibition (anti-PD1 antibody +/- ipilimumab) ii. Patients with locoregional or distant recurrence either during, or within 3 months after completion or discontinuation of (neo)adjuvant anti-PD1-based immunotherapy for stage III melanoma. b. Pancreatic cancer i. Patients with histologically proven metastatic pancreatic cancer with progression under or after standard first-line chemotherapy with FOLFIRINOX. 2. Patients must be willing and able to provide written informed consent and be willing and able to comply with the study protocol. 3. Patients must be ≥18 years of age. 4. Metastatic or locoregional lesion of which a tumour needle biopsy can be safely obtained according to routine clinical practice. Exclusion Criteria: \- Patients with metastatic or locally advanced lesions which are not considered to be technically and/or safely biopsied.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm melanoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma Pancreas cancer

Contacts and locations

Locations

  • Amsterdam UMC, location VUmc

    Amsterdam, 1081HZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.